Literature DB >> 8060802

Clinical review of lansoprazole.

S P Lockhart1.   

Abstract

Lansoprazole is an inhibitor of gastric H+,K(+)-ATPase, commonly referred to as the 'proton pump'. The pharmacodynamic effect of proton pump inhibition is to reduce gastric acid secretion. Long experience with H2 antagonists and more recently proton pump inhibitors has demonstrated the value of reducing gastric acid secretion in conditions where acid plays a key role in the pathogenesis of gastrointestinal inflammation and ulceration. The pharmacokinetics, pharmacodynamics and clinical safety of lansoprazole are discussed elsewhere in this supplement, and so this review will focus upon the European and American experience of the efficacy of lansoprazole in the treatment of peptic ulceration and gastro-oesophageal reflux.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8060802

Source DB:  PubMed          Journal:  Br J Clin Pract Suppl        ISSN: 0262-8767


  2 in total

1.  Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects.

Authors:  Chise Kodaira; Mitsushige Sugimoto; Masafumi Nishino; Mihoko Yamade; Naohito Shirai; Shinya Uchida; Mutsuhiro Ikuma; Shizuo Yamada; Hiroshi Watanabe; Akira Hishida; Takahisa Furuta
Journal:  Eur J Clin Pharmacol       Date:  2009-02-24       Impact factor: 2.953

2.  Determination of lansoprazole in biological fluids and pharmaceutical dosage by HPLC.

Authors:  A Avgerinos; T h Karidas; C Potsides; S Axarlis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Apr-Jun       Impact factor: 2.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.